NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Roche Holding AG (OTCMKTS:RHHBY) concerning possible violations of federal securities laws. On June 5, 2017, news reports stated that a new study showed that adding Roche Holding’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone. When this information was released, shares of Roche Holding fell in value. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.